Spots Global Cancer Trial Database for Validation of DNA Methylation Markers for Universal and Site-specific Guided Cancer Detection, VANGUARD Study

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Validation of DNA Methylation Markers for Universal and Site-specific Guided Cancer Detection, VANGUARD Study

Official Title: Validation of DNA Methylation Markers for the Universal and Site-Specific Guided Cancer Detection (the VANGUARD Study)

Study ID: NCT06304168

Conditions

Hematopoietic and Lymphatic System Neoplasm

Malignant Solid Neoplasm

Interventions

Non-Interventional Study

Study Description

Brief Summary: This study explores the potential value of a new blood test approach for early detection of cancer.

Detailed Description: PRIMARY OBJECTIVES: I. Validate candidate universal and site-specific MDMs in DNA extracted from formalin-fixed paraffin embedded primary tumor and control specimens. II. Test MDM-based models for detection of the top 16 most lethal human cancers using a non-invasive biological medium, specifically blood. III. Assess feasibility for detection of cancers using urine samples to assay MDMs, RNA or protein in cell free or extra-cellular vesicles; patients may be the same or unique individuals from Aim 1 and 2. OUTLINE: This is an observational study. Patients undergo blood, urine, and/or residual tissue sample collection and have their medical records reviewed on study.